Drug Profile


Alternative Names: '572-Trii; 572 Trii; Abacavir/GSK-1349572/lamivudine; Dolutegravir-Trii; Dolutegravir/abacavir/lamivudine; DTG/ABC/3TC; DTG/ABC/3TC FDC; GSK-1349572/abacavir/lamivudine; Lamivudine/abacavir/GSK-1349572; Triumeq

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline; Shionogi ViiV Healthcare LLC
  • Developer GlaxoSmithKline; Shionogi ViiV Healthcare LLC; ViiV Healthcare
  • Class Antiretrovirals; Cyclopentanes; Cyclopropanes; Dideoxynucleosides; Oxazines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; HIV replication inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 20 Dec 2016 ViiV Healthcare completes a phase I bioavailability trial in Healthy volunteers in USA (PO, Dispersible Tablet) (NCT02893488)
  • 18 Jul 2016 Efficacy and safety data from the phase III ARIA trial in HIV infections released by ViiV Healthcare
  • 05 Jul 2016 GlaxoSmithKline terminates the phase III ING200336 trial for HIV infections in USA and United Kingdom (PO) before July 2016 (NCT02075593)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top